Category: Professional Posters
Purpose: The objective of the study was to compare the clinical effectiveness of biological agents compared to other non-biological-based regimes in the management of RA. The most important measurements used to estimate the efficacy of the treatment were the following: DAS 28 score, ESR, CRP, anti-CCP, and RF. These markers were assessed for last twelve months of data observation and follow up after pharmaceutical intervention.
Methods: This cross-sectional study was conducted at a tertiary central hospital in Jazan, a southwestern region of Saudi Arabia. Real-world data of adults patients diagnosed with rheumatoid arthritis were retrospectively collected and analyzed the data of patients for patient’s following up in the outpatients clinics between September 2015 and September 2018. Ethical approval was obtained from the hospital's Institutional Review Board.
Statistical analysis was performed using the Statistical Package for Social Sciences version 24.0 for Windows (SPSS Inc., Chicago, IL, USA). Participants were categorized into three Groups: Group 1 received one biological agent; Group 2 received one or two disease-modifying anti-rheumatic drugs DMARDs; and Group 3 received the drugs of Group 1 plus 2. The biological agents include adalimumab, tocilizumab, etanercept, abatacept, infliximab, rituximab, and tofacitinib. The DMARDs involve methotrexate, sulfasalazine, hydroxychloroquine, and leflunomide. In addition, the Tukey HSD test was used for intergroup comparisons to evaluate any statistically significant differences between the groups being compared (overall α = .05)
Results: Demographic characteristics of the 316 patients who were identified from the hospital database meeting the inclusion criteria were as follow: 95% Saudi nationality, 89.2% female, and 52.5% in the age of 40-60 years. Baseline clinical markers were as follow: mean±SD of ESR was 46.14±31.14mm/h, CPR 1.32±1.98mg/L, and DAS was 2.74±0.80. After 12 months of treatment with individual drug of biological therapies. there were significant improvment in DAS for patinets used biological agent or a combination of DMRDS and biological medication, as illustrated in the following table:
Variables One way ANOVA
Medication used F P- Value
Group 1 Group 2 Group 3
ESR 32.37 ± 30.18 48.29 ± 30.90 46.53 ± 31.16 2.09 0.126
CRP 0.64 ± 0.79 1.59 ± 2.45 1.26 ± 1.82 2.03 0.133
DAS-ESR 2.22 ± 0.45 2.78 ± 0.77 2.76 ± 0.82 4.19 0.016*
Conclusion: This study showed that significant different between patients used biological medications only and patients who used DMARDs with biological medication.